NDP-001 (implied)
Congenital Pseudarthrosis of the Tibia (CPT)
Phase 1/2Active
Key Facts
Indication
Congenital Pseudarthrosis of the Tibia (CPT)
Phase
Phase 1/2
Status
Active
Company
About Novadip Biosciences
Novadip Biosciences is a private, clinical-stage biotech developing a new class of regenerative tissue products derived from adipose (fat) stem cells. The company's core technology platform aims to generate 3D tissues that mimic the natural healing environment, targeting critical challenges in orthopedics and reconstructive surgery. With a pipeline led by programs for congenital pseudarthrosis of the tibia (CPT) and spine fusion, Novadip is positioning itself in the high-growth cell and gene therapy sector. The company operates from Mont-Saint-Guibert, Belgium, and is likely pre-revenue, relying on partnerships and investment to advance its clinical programs.
View full company profile